Ensho Therapeutics files Form D for equity offering of up to $15.6 million
The Delaware biotechnology company reported $7,281,948 sold toward a total offering of $15,604,179, with a first sale date of October 2, 2026.
Ensho Therapeutics, Inc., a Delaware corporation based in Woodcliff Lake, New Jersey, filed a Form D notice with the Securities and Exchange Commission disclosing an exempt securities offering. The filing is a new notice with a date of first sale of October 2, 2026.1
The company classified itself under the biotechnology industry group. Ensho identified its industry as biotechnology within the health care sector.1
According to the offering details, the total offering amount is $15,604,179, with total amount sold of $7,281,948 and a remaining amount to be sold of $8,322,231.1
The offering relies on a specific regulatory exemption. Ensho claimed exemption under Rule 506(b).1 The securities offered include equity as well as a security to be acquired upon exercise of an option, warrant, or other right to acquire a security.1
The company reported a small investor base so far. The total number of investors who have already invested in the offering is seven.1 The minimum investment accepted from any outside investor is $1.1
No sales commissions or finder's fees were reported. Sales commissions and finders' fees are both listed as $0.1 The amount of proceeds used for payments to executive officers, directors, or promoters is also listed as $0.1
The filing lists several related persons, including Danielle Fry as an executive officer, and Arash Rassoulpour, Carlos Solorzano, Eric Pham, Gerhard Hagn, Neena Bitritto-Garg, and Tariq Kassum as directors.1 The notice was signed by Danielle Fry, Chief Legal Officer and Chief Operating Officer, on October 15, 2026.1 The company indicated it does not intend the offering to last more than one year.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.